- Home
- GNTA vs ANTX Comparison
GNTA vs ANTX Comparison
Compare GNTA & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | ANTX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 31.2M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | GNTA | ANTX |
|---|---|---|
| Price | $1.00 | $1.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 625.8K | 65.6K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $1.00 |
| 52 Week High | $10.00 | $1.49 |
Technical Indicators
Market Signals| Indicator | GNTA | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 43.31 |
| Support Level | $0.71 | $1.03 |
| Resistance Level | $1.70 | $1.16 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 85.53 | 33.33 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.